Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,235,366
  • Shares Outstanding, K 140,963
  • Annual Sales, $ 729,260 K
  • Annual Income, $ -451,290 K
  • 60-Month Beta 1.10
  • Price/Sales 7.09
  • Price/Cash Flow N/A
  • Price/Book 7.60
Trade IONS with:

Options Overview

Details
  • Implied Volatility 46.76%
  • Historical Volatility 38.16%
  • IV Percentile 30%
  • IV Rank 28.94%
  • IV High 68.74% on 02/10/21
  • IV Low 37.81% on 04/01/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 4,042
  • Volume Avg (30-Day) 681
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 26,761
  • Open Int (30-Day) 29,688

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.56
  • Number of Estimates 8
  • High Estimate -0.31
  • Low Estimate -0.83
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -143.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.65 +13.65%
on 07/15/21
40.02 -1.60%
on 07/06/21
-0.54 (-1.35%)
since 07/02/21
3-Month
34.43 +14.38%
on 06/07/21
40.33 -2.36%
on 07/01/21
-0.51 (-1.28%)
since 05/05/21
52-Week
34.43 +14.38%
on 06/07/21
64.37 -38.82%
on 01/26/21
-18.10 (-31.49%)
since 08/05/20

Most Recent Stories

More News
Ionis (IONS) Q2 Earnings & Revenues Fall Short of Estimates

Ionis (IONS) incurs wider-than-expected Q2 loss. The company maintains its sales guidance for 2021 but expects to incur more losses.

NVS : 92.25 (+0.72%)
BIIB : 336.59 (-0.45%)
IONS : 39.38 (+4.15%)
BCYC : 29.88 (+1.60%)
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1.79% and -9.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

IONS : 39.38 (+4.15%)
Ionis Pharmaceuticals: Q2 Earnings Snapshot

CARLSBAD, Calif. (AP) _ Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $81 million in its second quarter.

IONS : 39.38 (+4.15%)
Ionis reports second quarter 2021 financial results and recent business achievements

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2021 and recent business achievements.

IONS : 39.38 (+4.15%)
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-L, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development...

IONS : 39.38 (+4.15%)
NVS : 92.25 (+0.72%)
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen,...

IONS : 39.38 (+4.15%)
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IONS : 39.38 (+4.15%)
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

BIIB : 336.59 (-0.45%)
AMGN : 233.99 (+2.49%)
INCY : 76.92 (-0.54%)
MRNA : 416.26 (-0.67%)
MCRB : 6.98 (-1.55%)
IONS : 39.38 (+4.15%)
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

and , /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase placebo-controlled, multiple ascending dose clinical study...

BIIB : 336.59 (-0.45%)
IONS : 39.38 (+4.15%)
Ionis to hold second quarter 2021 financial results webcast

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on at to discuss its second quarter 2021 financial results and report on pipeline and business...

IONS : 39.38 (+4.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Key Turning Points

3rd Resistance Point 41.71
2nd Resistance Point 40.55
1st Resistance Point 39.97
Last Price 39.38
1st Support Level 38.22
2nd Support Level 37.06
3rd Support Level 36.48

See More

52-Week High 64.37
Fibonacci 61.8% 52.93
Fibonacci 50% 49.40
Fibonacci 38.2% 45.87
Last Price 39.38
52-Week Low 34.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar